ArticleInternational journal of radiation oncology, biology, physics2019
Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.
Article in International journal of radiation oncology, biology, physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers.Frontiers in pediatrics · 2026Article
- Proton Beam Therapy and the AYA Sarcoma Patient Journey: Highlighting Needs from Diagnosis to Survivorship.Cancers · 2025Review
- Proton Therapy Patient Selection Methods and the Impact of COVID-19: A Cross-Sectional International Survey.Journal of medical radiation sciences · 2025Article
- Article
- Radiotherapy Utilization in Traditional Medicare and Medicare Advantage.JAMA network open · 2025Article
- Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies.International journal of particle therapy · 2025Article
- Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact.Exploration of targeted anti-tumor therapy · 2025Review
- The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence From Radiation Oncology.Advances in radiation oncology · 2025Review
- Novel use of adjuvant proton beam therapy in patient with pelvic renal transplant diagnosed with stage IB3 cervical adenocarcinoma.Gynecologic oncology reports · 2024Article
- Health Disparities and Inequities in the Utilization of Proton Therapy for Prostate Cancer.Cancers · 2024Review
- How Long Can You Delay? Curve Progression While Awaiting Vertebral Body Tethering Surgery.Journal of clinical medicine · 2024Article
- How proton therapy fits into the management of adult intracranial tumors.Neuro-oncology · 2024Review
- Prompt Pain Relief From Bone Metastases: The Virtual Simulation Program.Advances in radiation oncology · 2024Article
- Survival among lung cancer patients: comparison of the U.S. military health system and the surveillance, epidemiology, and end results (SEER) program by health insurance status.Cancer causes & control : CCC · 2024Article
- Advances and Challenges in Conducting Clinical Trials With Proton Beam Therapy.Seminars in radiation oncology · 2023Review
- Pediatric Experience and Outcomes from the First Single-Vault Compact Proton Therapy Center.Cancers · 2023Article
- Insurance and racial disparities in prior authorization in gynecologic oncology.Gynecologic oncology reports · 2023Article
- Strategic Operational Redesign Improves Prior Authorization Access: A Validation Study.International journal of particle therapy · 2023Article
- Consolidative active scanning proton therapy for mediastinal lymphoma: selection criteria, treatment implementation and clinical feasibility.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.Cancers · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
purposePrior authorization (PA) has been widely implemented for proton beam therapy (PBT). We sought to determine the association between PA determination and patient characteristics, practice guidelines, and potential treatment delays. METHODS AND MATERIALS: A single-institution retrospective analysis was performed of all patients considered for PBT between 2015 and 2018 at a National Cancer Institute-designated Comprehensive Cancer Center. Differences in treatment start times and denial rates over time were compared, and multivariable logistic regression was used to identify predictors of initial denial.
resultsA total of 444 patients were considered for PBT, including 396 adult and 48 pediatric patients. The American Society for Radiation Oncology model policy supported PBT coverage for 77% of the cohort. Of adult patients requiring PA, 64% were initially denied and 32% remained denied after appeal. In patients considered for reirradiation or randomized phase 3 trial enrollment, initial denial rates were 57% and 64%, respectively. Insurance coverage was not related to diagnosis, reirradiation, trial enrollment, or the American Society for Radiation Oncology model policy guidelines, but it was related to insurance category on multivariable analysis (P < .001). Over a 3-year timespan, initial denial rates increased from 55% to 74% (P = .034). PA delayed treatment start by an average of 3 weeks (and up to 4 months) for those requiring appeal (P < .001) and resulted in 19% of denied patients abandoning radiation treatment altogether. Of pediatric patients, 9% were initially denied, all of whom were approved after appeal, and PA requirement did not delay treatment start (P = .47).
conclusionsPA requirements in adults represent a significant burden in initiating PBT and cause significant delays in patient care. Insurance approval is arbitrary and has become more restrictive over time, discordant with national clinical practice guidelines. Payors and providers should seek to streamline coverage policies in alignment with established guidelines to ensure appropriate and timely patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.